NASDAQ:IOBT IO Biotech - IOBT News Today Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding IO Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.65 -0.05 (-1.85%) (As of 02/6/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.53▼$2.9550-Day Range$2.30▼$3.0252-Week Range$2.15▼$9.77Volume70,123 shsAverage Volume120,963 shsMarket Capitalization$76.37 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address IOBT Media Mentions By Week IOBT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IOBT News Sentiment▼0.000.46▲Average Medical News Sentiment IOBT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IOBT Articles This Week▼00▲IOBT Articles Average Week All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineMorgan Stanley Reaffirms Their Buy Rating on IO Biotech (IOBT)markets.businessinsider.com - January 24 at 1:00 PMIO Biotech Announces Appointment of Devin Smith as General Counselfinance.yahoo.com - January 23 at 10:46 AMIO Biotech Provides Business Updatefinance.yahoo.com - January 9 at 7:55 AMAnalyst Says IO Biotech's Cancer Treatment Approach 'Differentiated'finance.yahoo.com - November 21 at 6:10 PMIO Biotech Announces Third Quarter Results for 2022finance.yahoo.com - November 9 at 9:22 PMIO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meetingfinance.yahoo.com - November 9 at 9:22 PMIO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumorsfinance.yahoo.com - November 3 at 11:35 AMIO Biotech to Participate in the Jefferies London Healthcare Conferencefinance.yahoo.com - October 31 at 9:39 AMAurion Biotech Wins Prestigious Prix Galien Startup Awardbusinesswire.com - October 30 at 12:06 AMIs IO Biotech (NASDAQ:IOBT) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - October 15 at 1:32 PMIO Biotech Announces Appointment of New Chief Financial Officerfinance.yahoo.com - October 13 at 5:48 PMIO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meetingfinance.yahoo.com - October 5 at 10:07 AMIO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conferencefinance.yahoo.com - September 6 at 8:27 AMIO Biotech Announces Second Quarter Results for 2022finance.yahoo.com - August 11 at 8:17 PMInotiv, IO Biotech top healthcare gainers; Regulus, Aerovate lead losers' packseekingalpha.com - July 19 at 11:01 PMIO Biotech to Participate in the 2022 BIO International Conventionfinance.yahoo.com - June 6 at 8:58 AMIO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022finance.yahoo.com - May 26 at 9:18 PMIO Biotech to Participate in the Jefferies Healthcare Conferencefinance.yahoo.com - May 23 at 6:10 PMIO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanomafinance.yahoo.com - May 18 at 11:28 AMIO Biotech Announces First Quarter Results for 2022finance.yahoo.com - May 16 at 5:26 PMWe're Not Very Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Ratefinance.yahoo.com - May 8 at 8:27 AMIO Biotech Hosting Key Opinion Leader Webinar Seriesfinance.yahoo.com - April 22 at 8:45 AMIO Biotech begins mid-stage trial of NSCLC candidate IO102-IO103seekingalpha.com - April 12 at 6:16 PMIO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trialfinance.yahoo.com - April 12 at 9:55 AMIO Biotech Reveals Updated Data From IO102-IO103/Opdivo Combo Trial In Melanomafinance.yahoo.com - April 11 at 5:08 PMIO Biotech Inc (IOBT)investing.com - April 10 at 5:08 AMIO Biotech posts positive data from metastatic melanoma therapy trialseekingalpha.com - April 8 at 5:44 PMIO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meetingfinance.yahoo.com - April 8 at 5:44 PMIO Biotech reports FY resultsseekingalpha.com - March 31 at 6:41 PMSUNW, CEI and HNRG among mid-day moversseekingalpha.com - March 9 at 10:24 AMIO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022finance.yahoo.com - March 8 at 7:47 PMIO Biotech Announces Appointment of David V. Smith to its Board of Directorsfinance.yahoo.com - March 3 at 6:01 PMWhat Kind Of Investors Own Most Of IO Biotech, Inc. (NASDAQ:IOBT)?finance.yahoo.com - February 7 at 8:54 AMCould The IO Biotech, Inc. (NASDAQ:IOBT) Ownership Structure Tell Us Something Useful?nasdaq.com - February 5 at 1:59 PMIO Biotech Announces Publication of Phase 1/2 Melanoma Clinical Trial Results in Nature Medicinefinance.yahoo.com - December 9 at 1:28 PMIO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trialfinance.yahoo.com - December 6 at 8:41 AMIO Biotech Trading 21% Highernasdaq.com - December 3 at 3:00 PMIO Biotech, Inc. (IOBT)realmoney.thestreet.com - December 2 at 11:55 PM Get IO Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for IOBT and its competitors with MarketBeat's FREE daily newsletter. Email Address This page (NASDAQ:IOBT) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.